바이오인

 

 

 

Despite being theorized more than 100 years ago as the “magic bullets” to treat a range of diseases, it is only within the last 10 years that antibodies have become an important class of therapeutics. This meeting will bring together experts from academia and industry to discuss the current state of antibody therapeutics, their mechanism of action in a range of medical indications, novel approaches to improving discovery, manufacturing, formulation, and pharmacokinetics, methods to predict and increase therapeutic efficacy, as well as novel therapeutic opportunities in cancer, infectious diseases, allergy, inflammatory diseases, and the neurosciences. This meeting will be of interest to academic and industry scientists working in all these fields.

 

 

 

Friday, March 27
3:00 - 7:30 PM  Registration                                                                             Foyer 
6:30 - 7:30 PM  Refreshments                                                                         Foyer 
7:30 - 8:30 PM  Keynote Address (Joint)                                         Sea to Sky Ballroom B,C 
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  
David P. Lane, Experimental Therapeutic Centre, Singapore
Cancer Target Validation: The use of chemical biology and protein aptamer approaches  
  
  

Saturday, March 28
7:00 - 8:00 AM  Breakfast                                              Sea to Sky Ballroom A, Lower Level  7:00 - 8:00 AM  Poster Setup                          Foyer/Mountain View/Sea to Sky Ballroom A 
8:00 - 11:00 AM  Novel Cancer Drug Scaffolds (Joint)
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B,C  
Andreas G. Plückthun, University of Zürich, Switzerland
Ankyrin Repeat Proteins   
Nick Terrett, Ensemble Discovery Corp., USA
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds  
Gregory L. Verdine, Harvard University, USA
Drugging “Undruggable” Targets Using Stapled Peptides  
David Baker†, University of Washington, USA
Talk Title to be Determined   
9:20 - 9:40 AM  Coffee Break                                                                  Foyer 
11:00 AM- 12:00 PM  Lunch                                       Foyer/Sea to Sky Ballroom A 
12:00 - 2:30 PM  Poster Session 1
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Foyer/Mountain View/Sea to Sky Ballroom A 
2:30 - 4:30 PM  Workshop 1: Novel Approaches to Cancer Drug Development (Joint)
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  
Steve K. Horrigan, Avalon Pharmeceuticals, USA
Systems Biology for Lead Optimization  
Lutz Jermutus, MedImmune Ltd, UK
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies  

4:30 - 5:00 PM  Coffee Available                                                                    Foyer 
5:00 - 7:00 PM  Generating and Engineering Novel Antibody Binding Sites
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B 
George Georgiou, University of Texas at Austin, USA
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli  
James D. Marks, University of California, San Francisco, USA
Selecting Internalizing Antibodies for Drug Delivery  
Andrew R. M. Bradbury, Los Alamos National Laboratory, USA
High-throughput Selection and Screening of Single-chain Antibodies  
Following Session is for Targeted Cancer Therapies (X8)
5:00 - 7:00 PM  The Chemistry of Targeted Drug Discovery
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom C  
James E. Bradner, Dana-Farber Cancer Institute, USA
Next-Generation Histone Deacetylase Inhibitors   
Saul H. Rosenberg, Abbott Laboratories, USA
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors   
Nathanael Gray, Dana-Farber Cancer Center, USA
Talk Title to be Determined  

7:00 PM-  On Own for Dinner  

 

Sunday, March 29
7:00 - 8:00 AM  Breakfast                                     Sea to Sky Ballroom A, Lower Level 
8:00 - 11:00 AM  Engineering Fc Regions for Optimized ADCC and PK
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B 
Louis M. Weiner, Georgetown University Medical Center, USA
Optimizing in vitro and in vivo ADCC for Cancer Therapy  
John R. Desjarlais, Xencor, USA
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics   
Pablo Umaña, GlycArt Biotechnology AG, Switzerland
New Glycoengineered Antibodies with Enhanced Effector Functions  
E. Sally Ward, University of Texas Southwestern Medical Center, USA
The role of FcRn in IgG homeostasis: implications for the use of antibodies in therapy  
Following Session is for Targeted Cancer Therapies (X8)
8:00 - 11:00 AM  Cancer Targets
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom C  
Pierre Sonveaux, University of Louvain (UCL) Medical School, Belgium
Lactate-fueled Tumor Cell Respiration: a New Paradigm and a New Target for Therapy   
Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
HSP90 as a Cancer Drug Target  
Craig B. Thompson, Abramson Family Cancer Center and Research Institute, University of Pennsylvania, USA
Mitochondrial Targets  
D. Gary Gilliland, Brigham and Women's Hospital, USA
Genome Wide shRNA-Based Synthetic Lethality Screens to Target "Undruggable" Cancer Disease Alleles  

9:20 - 9:40 AM  Coffee Break                                                              Foyer 
11:00 AM-  On Own for Lunch  
11:00 AM- 1:00 PM  Poster Setup                  Foyer/Mountain View/Sea to Sky Ballroom A 
1:00 - 10:00 PM  Poster Viewing                    Foyer/Mountain View/Sea to Sky Ballroom A 
2:30 - 4:30 PM  Workshop 1                                                 Sea to Sky Ballroom B  
Short Talks to be Chosen from Abstracts, , USA 
4:30 - 5:00 PM  Coffee Available                                                         Foyer 
5:00 - 7:00 PM  Immune System Activation to Elicit Therapeutic Responses
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B  
Raphael Clynes, Columbia University, USA
Conversion of Passive Antibody Therapy to Active Immunity  
Jacques F. Banchereau, Baylor Institute for Immunology Research, USA
Targeting DCs for Anti-Tumor Immunity   
Kavita Dhodapkar, Rockefeller University, USA
Antibody-Based Induction of Adaptive Immune Response  
Following Session is for Targeted Cancer Therapies (X8)
5:00 - 7:00 PM  Autophagy and Metabolism
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009                                                                           Sea to Sky Ballroom C 
Matthew Vander Heiden, Harvard University, USA
Targeting Cancer Cell Metabolism  
Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting Energy Sensing  
Chi Van Dang, Johns Hopkins University School of Medicine, USA
Therapeutic Implications of the Warburg Effect  

7:00 - 8:00 PM  Social Hour w/ Lite Bites  Foyer/Mountain View/Sea to Sky Ballroom A 
7:30 - 10:00 PM  Poster Session 2
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Foyer/Mountain View/Sea to Sky Ballroom A 

 

Monday, March 30
7:00 - 8:00 AM  Breakfast                                            Sea to Sky Ballroom A, Lower Level 
8:00 - 11:00 AM  Antibodies for Treatment of Cancer
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B 
Mark X. Sliwkowski, Genentech, Inc., USA
HER2 Targeted Therapies  
Andrew M. Scott, Ludwig Institute for Cancer Research, Australia
Targeting a Novel EGFR Epitope on Cancer Cells  
Kerry Chester, University College London, UK
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer  
Philip E. Thorpe, University of Texas Southwestern Medical Center, USA
Targeting the Vasculature for Tumor Therapy  
Following Session is for Targeted Cancer Therapies (X8)
8:00 - 11:00 AM  Novel Target Discovery
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom C 
Alan Ashworth, Institute of Cancer Research, UK
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer  
William G. Kaelin Jr., Dana Farber Cancer Institute, USA
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases   
Lynda Chin, Dana Farber Cancer Institute, USA
Mining and Translating the Cancer Genome  
Stuart L. Schreiber†, Harvard University, USA
Talk Title to be Determined  
 Short Talk(s) to be Chosen from Abstracts, 
9:20 - 9:40 AM  Coffee Break                                                                Foyer 
11:00 AM- 1:00 PM  Poster Setup           Foyer/Mountain View/Sea to Sky Ballroom A 
11:00 AM-  On Own for Lunch  
1:00 - 10:00 PM  Poster Viewing               Foyer/Mountain View/Sea to Sky Ballroom A 
2:30 - 4:30 PM  Workshop 2: Therapeutic Antibodies in the Neurosciences
 Sea to Sky Ballroom B 
Eric V. Shusta, University of Wisconsin, Madison, USA
Novel Approaches to Traffic Across the Blood Brain Barrier  
Anne Messer, Wadsworth Center, USA
Intrabodies for Neurodegeneration Disorders   
Anthony Williamson, Calmune Corporation, USA
Antibodies for Prion Based Diseases  
Following Workshop is for Targeted Cancer Therapies (X8)
2:30 - 4:30 PM  Workshop 2: Epigenetic Targeting
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom C 
Peter A. Jones, University of Southern California, USA
Epigenetic Therapy   
Alan Colowick, Gloucester Pharmaceuticals, USA
Talk Title to be Determined   
4:30 - 5:00 PM  Coffee Available                                                    Foyer 
5:00 - 7:00 PM  Identifying and Predicting Antibody Efficacy and Toxicity
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B 
Peter D. Senter, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy   
Birgit Schoeberl, Merrimack Pharmaceuticals, USA
An attempt to translate in vitro responses into the clinic using computationally predicted preclinical data from ErbB Targeted therapies  
Richard H.J. Begent, University of College London, UK
Guidelines for information about antibody therapy experiments; lessons from the Tegenero experience  
Following Session is for Targeted Cancer Therapies (X8)
5:00 - 7:00 PM  Target Validation
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom C 
Dean Walton Felsher, Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models   

7:00 - 8:00 PM  Social Hour w/ Lite Bites  Foyer/Mountain View/Sea to Sky Ballroom A 
7:30 - 10:00 PM  Poster Session 3
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Foyer/Mountain View/Sea to Sky Ballroom A 

Tuesday, March 31
7:00 - 8:00 AM  Breakfast                                       Sea to Sky Ballroom A, Lower Level 
8:00 - 11:15 AM  Antibodies in the Treatment of Autoimmunity, Allergy and Infectious Diseases
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B 
Ian A. Wilson, The Scripps Research Institute, USA
Structural Aspects of Antibody Recognition of Influenza   
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Monoclonal Antibodies from Memory B cells  
Dennis R. Burton, The Scripps Research Institute, USA
Antibodies for HIV Therapy and Vaccine Development  
John Haurum, Symphogen, Denmark
Capturing the Natural Humoral Immune Response by Symplex  
Tariq Ghayur, Abbott Bioresearch Center, USA
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics  
Following Session is for Targeted Cancer Therapies (X8)
8:00 - 11:00 AM  Targeted Therapy Response Prediction
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom C 
Joe W. Gray, Lawrence Berkeley National Laboratory, USA
Predicting Targeted Drug Response   
Barbara L. Weber, GlaxoSmithKline, USA
Using Cancer Genomics to Inform Targeted Drug Development  
Sanford D. Markowitz, Case Western Reserve University, USA
Genetic Targets in Colon Cancer   
Tak W. Mak, Campbell Family Institute for Breast Cancer Research at PMH, UHN, Canada
Talk Title to be Determined  

9:20 - 9:40 AM  Coffee Break                                                                           Foyer 
11:15 AM-  On Own for Lunch  
4:30 - 5:00 PM  Coffee Available                                                                      Foyer 
5:00 - 7:00 PM  Imaging in Cancer Drug Discovery (Joint)
Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009  Sea to Sky Ballroom B,C 
Roger Y. Tsien, University of California, San Diego, USA
Optical and MR imaging of tumors in vivo with activatable cell penetrating peptides  
Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation  
Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Probing Cell Surface Markers in vivo  

7:00 - 8:00 PM  Social Hour w/ Lite Bites  Foyer/Mountain View/Sea to Sky Ballroom A 
8:00 - 11:00 PM  Entertainment  Foyer/Mountain View/Sea to Sky Ballroom A 

 

Wednesday, April 1
 Departure 

 

- You may register for this meeting on this web site until March 27, 2009.
- The Registration Fee includes the Abstract Submission Fee.
- For more information and other registration options, see How to Register.

Non-Student Fees
- The Registration Fee is $725.00 on and before January 27, 2009.
- After January 27, 2009, the Registration Fee is $825.00

Student Fees
- To qualify for the Student Discount, you must complete the Student Verification section of the Registration Form.
- The Student Registration Fee is $500.00 on and before January 27, 2009.
- After January 27, 2009, the Registration Fee is $600.00